Confluence Wealth Services Inc. Sells 1,241 Shares of Johnson & Johnson (NYSE:JNJ)

Confluence Wealth Services Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,308 shares of the company’s stock after selling 1,241 shares during the period. Johnson & Johnson comprises about 0.5% of Confluence Wealth Services Inc.’s portfolio, making the stock its 27th largest position. Confluence Wealth Services Inc.’s holdings in Johnson & Johnson were worth $4,751,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Moneta Group Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $4,609,399,000. Morgan Stanley raised its position in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. Barclays PLC raised its position in Johnson & Johnson by 61.0% during the 2nd quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock worth $1,868,351,000 after buying an additional 4,278,512 shares during the last quarter. Finally, Imprint Wealth LLC raised its position in Johnson & Johnson by 17,087.7% during the 2nd quarter. Imprint Wealth LLC now owns 2,913,480 shares of the company’s stock worth $291,348,000 after buying an additional 2,896,529 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on JNJ. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, March 13th. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 28th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Raymond James boosted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Finally, Morgan Stanley decreased their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $177.31.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $147.52 on Friday. The firm has a market cap of $355.49 billion, a PE ratio of 10.68, a PEG ratio of 2.50 and a beta of 0.53. The firm has a fifty day moving average of $157.24 and a 200 day moving average of $155.98. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm’s revenue was down 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.35 EPS. As a group, research analysts predict that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.